Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange. In response to one viewer looking for insight on Dunkin' Brands (DNKN), Cramer says the company is good because it's still expanding nationwide from east to west as the price of coffee has come down. However, he believes that Starbucks (SBUX), which he owns in his Action Alerts PLUS charitable trust portfolio, is better. He reveals that he figured the stock would be down a dollar or so today and he was prepared to recommend that people buy it. Being as that didn't happen, Cramer says investors might still get a chance to buy it lower but either way, that's the one to own over Dunkin'. Cramer also weighs in on the PayPal initial public offering. He says he would be a buyer of it now because he believes PayPal is very viable and he doesn't think the rest of eBay (EBAY) is that bad. In the cyber security space, another viewer asks if Cramer recommends being a buyer of dips in names within the group, specifically FireEye (FEYE). Cramer sheds light on comments made by Dave DeWalt, chairman and chief executive officer at FireEye, on CNBC's 'Mad Money' and stresses that he continues to believe that FireEye is a great place to go. If you have a stock question, tweet it @jimcramer using #CramerQ.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.